Advances in the RLL assessment system based on 18F-FDG PET/CT for predicting therapeutic effect and prognostic efficacy of DLBCL
10.3760/cma.j.cn321828-20240418-00137
- VernacularTitle:基于 18F－FDG PET/CT的RLL评估系统预测DLBCL疗效及预后效能的最新进展
- Author:
Zhongming SHI
1
;
Lu WANG
;
Jun XIN
Author Information
1. 中国医科大学附属盛京医院核医学科，沈阳 110004
- Publication Type:Journal Article
- Keywords:
Lymphoma, large B-cell, diffuse;
Positron-emission tomography;
Tomography, X-ray computed;
Fluorodeoxyglucose F18;
Trends;
RLL
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(4):249-252
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma(DLBCL), as the most common subtype of non-Hodgkin′s lymphoma, requires precise assessment of treatment efficacy and prognosis for optimal patient care planning. 18F-FDG PET/CT, an advanced imaging technique, has become a standard tool for evaluating treatment outcomes and predicting prognoses in patients with DLBCL. Currently, the Deauville scoring system, based on a 5-point visual analog scale, is the predominant method for assessing treatment efficacy and prognosis. However, the ambiguity of some scoring criteria and the subjectivity in interpretation somewhat limit its clinical application value. In recent years, a novel semi-quantitative method, the ratio of the SUV max of the lesion to the SUV of the liver (RLL), has gained attention and shown promise in the evaluation of treatment efficacy and prognostic analysis for DLBCL. This article aims to review the application of the RLL evaluation system in the assessment of DLBCL efficacy and prognosis, the latest research advancements, and the future development trends.
